Skip to content

Reducing Blood Culture Contamination:

Reducing Blood Culture Contamination: a Prospective Crossover Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02754791
Enrollment
1500
Registered
2016-04-28
Start date
2016-05-31
Completion date
2017-05-31
Last updated
2016-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preventing Blood Culture Contamination

Brief summary

Bloodstream infections cause significant morbidity and mortality and their prompt identification is an essential part of modern medicine. False positive results in blood cultures are primarily due to contaminants. It has been estimated that up to 50% of positive blood cultures represent contamination. These false positive cultures, at the microbiological laboratory level, require significant additional resources for workup. Additionally, they result in unnecessary antibiotic treatment and hospitalization days, causing needless harm to patients. Various methods have been implemented in order to reduce blood culture contaminants, including modifying the solution used for sterilizing the skin and feedback on contamination rates. However, it has been shown that the bacteria which colonize the human skin are not only on the surface but in fact colonize deeper surfaces as well. The SteriPath device diverts the initial 1-2 ml blood so as to remove any potential skin plug with contaminants. Thus, the principle object of this study is the determination of the rate of contamination of blood culture taken prior to initiating intervention versus the rate of contamination using three interventions: Monthly feedback via departmental report card, a chlorhexidine plus alcohol wipe and the SteriPath device. Secondary objectives will include ease of use of the wipes and the SteriPath device and an estimate of the sensitivity of SteriPath device use to true bacteremia. If the various interventions will be shown to reduce contamination, researchers will also attempt to estimate the financial effects of those reductions, comparing intervention cost to estimated savings related to reduced contamination.

Interventions

DEVICESteripath

A device that diverts the first 2 ml of blood drawn in order to reduce contamination

DEVICESoluprep

Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization

Sponsors

Magnolia Medical Technologies, Inc.
CollaboratorINDUSTRY
3M
CollaboratorINDUSTRY
Shaare Zedek Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adult patients hospitalized in our institution in whom blood cultures are taken

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
Percentage of contaminated blood cultures relative to overall blood cultures as compared to percentage in historical and parallel control groups6 months

Secondary

MeasureTime frame
Ease of use of SteriPath device as evaluated by resident physicians and phlebotomists using a questionaire6 months
Cost effectiveness of Steripath device and chlorhexidine wipes in measured as cost of devices in dollars versus reduction of cost in dollars associated with reduced blood culture contamination6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026